Details

Autor(en) / Beteiligte

• Olanow, C. Warren
• Rascol, Olivier
• Hauser, Robert
• Feigin, Paul D
• Jankovic, Joseph
• Lang, Anthony
• Langston, William
• Melamed, Eldad
• Poewe, Werner
• Stocchi, Fabrizio
• Tolosa, Eduardo

Titel

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

Ist Teil von

• The New England journal of medicine, 2009-09, Vol.361 (13), p.1268-1278

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• This double-blind trial was designed to determine whether rasagiline slows the progression of Parkinson's disease. As compared with delayed treatment, early treatment with rasagiline at a dose of 1 mg per day achieved benefits consistent with a disease-modifying effect, but 2 mg per day did not result in similar benefits. As compared with delayed treatment, early treatment with rasagiline at a dose of 1 mg per day achieved benefits consistent with a disease-modifying effect, but 2 mg per day did not result in similar benefits. A neuroprotective therapy that slows or stops disease progression is the major unmet medical need in Parkinson's disease. 1 Although current therapies provide beneficial effects on symptoms that help control the classic motor features of the disease (i.e., tremor, rigidity, and bradykinesia), intolerable disability eventually develops in most patients. 2 Numerous agents have neuroprotective effects in laboratory models, but none have been shown to have disease-modifying effects in patients with Parkinson's disease. 3 A limiting factor is the requirement for a clinical end point that reliably measures disease progression and is not confounded by the study intervention's effects on symptoms. The delayed-start design . . .